Melanoma is an aggressive malignancy originating from pigment-producing melanocytes.
The development of targeted therapies (MAPK pathway inhibitors) and immunotherapies …

Drug resistance constitutes a major challenge in designing melanoma therapies.
Microenvironment-driven tumor heterogeneity and plasticity play a key role in this …

Tumor recurrence years after seemingly successful treatment of primary tumors is one of the
major causes of mortality in patients with cancer. Reactivation of dormant tumor cells is …

Abstract Background Circular RNAs (circRNAs) have important regulatory functions in
cancer, but the role of circRNAs in the tumor microenvironment (TME) remains unclear …

Highlights•SERPINE2 knockdown inhibits radioresistance and DNA damage repair by
mediating RAD51 in lung cancer.•SERPINE2 promotes ATM phosphorylation by directly …

It is increasingly appreciated that cancer cell heterogeneity and plasticity constitute major
barriers to effective clinical treatments and long-term therapeutic efficacy. Research in the …

Simple Summary Tumour heterogeneity is a phenomenon where the cancer cells evolve
diversely over the course of the disease. As a result of the evolution, the cancer cells can be …

Metastatic melanoma is an aggressive disease, despite recent improvements in therapy.
Eradicating all melanoma cells even in drug-sensitive tumors is unsuccessful in patients …

Melanoma, the deadliest skin cancer, remains largely incurable at advanced stages.
Currently, there is a lack of animal models that resemble human melanoma initiation and …

Cancer cell heterogeneity is a universal feature of human tumors and represents a
significant barrier to the efficacy and duration of anticancer therapies, especially targeted …